1. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al.; American Diabetes Association. Retinopathy in diabetes. Diabetes Care. 2004;27:S84-7. https://doi.org/10.2337/diacare.27.2007.S84 https://pubmed.ncbi.nlm.nih.gov/14693935 
2. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30(5):343-58. https://doi.org/10.1016/j.preteyeres.2011.05.002 https://pubmed.ncbi.nlm.nih.gov/21635964 
3. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res. 2008;27(6):622-47. https://doi.org/10.1016/j.preteyeres.2008.09.003 https://pubmed.ncbi.nlm.nih.gov/18940262 
4. Ishizaki E, Takai S, Ueki M, Maeno T, Maruichi M, Sugiyama T, et al. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol. 2006;141(1):129-34. https://doi.org/10.1016/j.ajo.2005.08.066 https://pubmed.ncbi.nlm.nih.gov/16386986 
5. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood. 2000;96(8):2673-81. https://doi.org/10.1182/blood.V96.8.2673 https://pubmed.ncbi.nlm.nih.gov/11023497 
6. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4(12):e8158. https://doi.org/10.1371/journal.pone.0008158 https://pubmed.ncbi.nlm.nih.gov/19997642 
7. Chan CC, Smith WM. Inflammatory Response and Mediators in Retinal Injury. In: Ryan SJ, editor. Retina. 5th ed. Philadelphia: W.B. Saunders; 2013. pp. 553-61. https://doi.org/10.1016/B978-1-4557-0737-9.00025-4 
8. Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw. 2006;17(3):155-65. https://pubmed.ncbi.nlm.nih.gov/17194635 
9. Abu El-Asrar AM, Nawaz MI, Kangave D, Mairaj Siddiquei M, Geboes K. Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. J Diabetes Res. 2013;2013:539658. https://doi.org/10.1155/2013/539658 https://pubmed.ncbi.nlm.nih.gov/23671874 
10. Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res. 2012;37(5):416-20. https://doi.org/10.3109/02713683.2012.661114 https://pubmed.ncbi.nlm.nih.gov/22409294 
11. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-7. https://doi.org/10.1056/NEJM199412013312203 https://pubmed.ncbi.nlm.nih.gov/7526212 
12. Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Takeuchi M, Goto H, et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina. 2010;30(2):339-44. https://doi.org/10.1097/IAE.0b013e3181bd2f44 https://pubmed.ncbi.nlm.nih.gov/20142713 
13. El-Asrar AM, Nawaz MI, Kangave D, Geboes K, Ola MS, Ahmad S, et al. High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy. Mol Vis. 2011;17:1829-38. https://pubmed.ncbi.nlm.nih.gov/21850157 
14. Capeans C, De Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina. 1998;18(6):546-50. https://pubmed.ncbi.nlm.nih.gov/9869464 
15. Abu el Asrar AM, Maimone D, Morse PH, Gregory S, Reder AT. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 1992;114(6):731-6. https://doi.org/10.1016/S0002-9394(14)74052-8 https://pubmed.ncbi.nlm.nih.gov/1463043 
16. Petrovič MG, Korošec P, Košnik M, Hawlina M. Association of preoperative vitreous IL-8 and VEGF levels with visual acuity after vitrectomy in proliferative diabetic retinopathy. Acta Ophthalmol. 2010;88(8):e311-6. https://doi.org/10.1111/j.1755-3768.2010.02030.x https://pubmed.ncbi.nlm.nih.gov/21073666 
17. Petrovic MG, Korošec P, Košnik M, Hawlina M. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2007;143(1):175-6. https://doi.org/10.1016/j.ajo.2006.07.032 https://pubmed.ncbi.nlm.nih.gov/17188064 
18. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond). 2006;20(12):1366-9. https://doi.org/10.1038/sj.eye.6702138 https://pubmed.ncbi.nlm.nih.gov/16284605 
19. Dai Y, Wu Z, Wang F, Zhang Z, Yu M. Identification of chemokines and growth factors in proliferative diabetic retinopathy vitreous. BioMed Res Int. 2014;2014:486386. https://doi.org/10.1155/2014/486386 https://pubmed.ncbi.nlm.nih.gov/25401103 
20. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94(9):3171-82. https://doi.org/10.1210/jc.2008-2534 https://pubmed.ncbi.nlm.nih.gov/19509100 
21. Hang H, Yuan S, Yang Q, Yuan D, Liu Q. Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy. Mol Vis. 2014;20:1137-45. https://pubmed.ncbi.nlm.nih.gov/25253986 
22. Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis. 2009;15:1906-14. https://pubmed.ncbi.nlm.nih.gov/19784389 
23. Doganay S, Evereklioglu C, Er H, Türköz Y, Sevinç A, Mehmet N, et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond). 2002;16(2):163-70. https://doi.org/10.1038/sj/eye/6700095 https://pubmed.ncbi.nlm.nih.gov/11988817 
24. Taghavi Y, Hassanshahi G, Kounis N, Koniari I, Khorramdelazad H. Monocyte Chemoattractant protein-1 (MCP-1/CCL2) in Diabetic Retinopathy: Latest Evidence and Clinical Considerations. J Cell Commun Signal. 2019;13(4):451-62. https://doi.org/10.1007/s12079-018-00500-8 https://pubmed.ncbi.nlm.nih.gov/30607767 
25. Simó-Servat O, Hernández C, Simó R. Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy. Mediators Inflamm. 2012;2012:872978. https://doi.org/10.1155/2012/872978 https://pubmed.ncbi.nlm.nih.gov/23028204 
26. Tsai T, Kuehn S, Tsiampalis N, Vu MK, Kakkassery V, Stute G, et al. Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients. PLoS One. 2018;13(3):e0194603. https://doi.org/10.1371/journal.pone.0194603 https://pubmed.ncbi.nlm.nih.gov/29584759 
27. Zorena K, Raczyńska D, Raczyńska K. Biomarkers in diabetic retinopathy and the therapeutic implications. Mediators Inflamm. 2013;2013:193604. https://doi.org/10.1155/2013/193604 https://pubmed.ncbi.nlm.nih.gov/24311895 
28. Mao C, Yan H. Roles of elevated intravitreal IL-1β and IL-10 levels in proliferative diabetic retinopathy. Indian J Ophthalmol. 2014;62(6):699-701. https://doi.org/10.4103/0301-4738.136220 https://pubmed.ncbi.nlm.nih.gov/25005199 
29. Hernández C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simó R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2005;22(6):719-22. https://doi.org/10.1111/j.1464-5491.2005.01538.x https://pubmed.ncbi.nlm.nih.gov/15910622 
30. Maier R, Weger M, Haller-Schober EM, El-Shabrawi Y, Wedrich A, Theisl A, et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis. 2008;14:637-43. https://pubmed.ncbi.nlm.nih.gov/18385799 
